Research programme: small molecule therapeutics - Hetero Labs/Sihuan Pharmaceutical
Alternative Names: Coronovirus (2019-nCoV) therapeuticsLatest Information Update: 28 Mar 2024
At a glance
- Originator Hetero Biopharma; Sihuan Pharmaceutical Holdings Group
- Class Anti-infectives; Antivirals; Cardiovascular therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported COVID 2019 infections; Vascular disorders
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in China
- 28 Mar 2024 No recent reports of development identified for research development in COVID-2019-infections in India
- 28 Mar 2024 No recent reports of development identified for research development in Vascular-disorders in China